[1] | Agaeva, N. A. The role of secretory IGA in the pathology of the maxillofacial region / N. A. Agaeva // Fundamental research. - 2010. - No. 4. - P. 11-16. |
[2] | Adsorption of microbes of mixed saliva by various orthopedic materials / N. V. Rozhkova, V. A. Labunets, V. E. Zavadsky, A. P. Levitsky // Bulletin of Dentistry. - 2011. - No. 1. - P. 66-69. |
[3] | Antimicrobial activity of lysozyme as a factor of non-specific resistance / A. I. Goncharova, V. K. Okulich, V. Yu. Zemko, S. A. Senkovich // Bulletin of VSMU. - 2019. - No. 4. - P. 40 -45. |
[4] | Arzukanyan, A. V. Optimization of the oral hygiene care protocol in patients with diseases of the mucous membrane: diss… candidate of medical sciences: 14.01.14 / Arzukanyan Alina Vladimirovna; First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of the Russian Federation (Sechenov University). - Moscow, 2021. - 134 p. |
[5] | Afanasyeva, A. S. Colonization of prosthetic and filling materials by oral microflora / A.S. Afanasyeva // Siberian Medical Review. - 2007. - No. 4. - P. 50-54. |
[6] | The influence of the buffer system on the remineralization of hard dental tissues / M.N. Mitropanova, O.A. Pavlovskaya, M.S. Zneybat, N.S. Sinitsina // Chief Physician of the South of Russia. – 2013. – No. 6. – No. 37. – P. 69–75. |
[7] | Dzarasova, M. A. Specific properties and functions of saliva as a mineralizing fluid / M. A. Dzarasova, O. V. Neyolova // International Student Scientific Bulletin. – 2017. – No. 4–6. – URL: https://eduherald.ru/ru/article/view?id=17596 (date of access: 04/24/2024). – Text: electronic. |
[8] | Elovikova, T. M. Saliva as a biological fluid and its role in oral health: a tutorial / T. M. Elovikova, S. S. Grigoriev – Ekaterinburg: Publishing House "TIRAZH", 2018. – 136 p. – ISBN 978–5–89895–892–3. –Text: direct. |
[9] | Karaulova, A. V. Clinical immunology and allergology / A. V. Karaulova. – Moscow: Medical information agency. – 2002. – 651 p. – ISBN 978–5–894–81079–9. –Text: direct. |
[10] | Katola, V. M. The role of the oral microbiome in the development of inflammation and somatic pathology / V. M. Katola, V. E. Komogortseva // Bull. phys. and pat. res. – 2018. – No. 68. – P. 117. |
[11] | Pozharitskaya, M. M. The role of saliva in the development of the pathological process in the hard and soft tissues of the oral cavity: xerostomia: a methodological manual / M.M. Pozharitskaya. - Moscow: GOU VUNMU, 2001. - 48 p. - ISBN 5–89004–135–5. - Text: direct. |
[12] | The use of high doses of methotrexate in children with cancer: features of concomitant therapy, toxicity assessment / Yu.V. Dinikina, A.Yu. Smirnova A.Yu., K.M. Golubeva [et al.] // RZhGIO. - 2018. - No. 2. - P. 11–18. |
[13] | Romanenko, I. G. Prediction of oral mucositis symptoms in patients with oral mucosa cancer / I. G. Romanenko, A. A. Dzherelei, K. A. Arakelyan // Current issues of medical prevention, diagnostics and treatment of dental diseases: Coll. art. int. scientific–practical. conf., Minsk, May 17, 2019 / Belarusian State Medical University, 2nd dep. of therapeutic dentistry; under the general editorship of T. N. Manak, L. G. Borisenko, L. N. Polyanskaya. – Minsk, 2019. – Pp. 151–153. |
[14] | Radjapova, M.U. Comparative assessment of mucosal reactions in multi-fractional chemoradiotherapy of oral and oropharyngeal cancer / M.U. Radjapova, Yu.S. Mardynsky, I.A. Gulidov // Siberian Cancer Journal. – 2011. – № 1. – pp. 12-15. |
[15] | Stepanova, T. Yu. Microbiome of the human oral cavity / T. Yu. Stepanova, A. V. Timofeeva // Modern problems of science and education. – 2016. – No. 5. – URL: https://science–education.ru/ru/article/view?id=25212 (date accessed: 14.04.2024). – Text: electronic. |
[16] | Enhancement of the cytotoxic effect of 5-fluorouracil with combined use with ultrasound / D.I. Vodolazhsky, N.A. Nazaralieva, T.I. Moiseenko [et al.] // News of universities. North Caucasus region. Series: Natural sciences. – 2018. – No. 2. – P. 100–105. |
[17] | Basson, M. D. In vitro evidence for matrix regulation of intestinal epithelial biology during mucosal healing / M.D. Basson // Life Sci. – 2001. – Vol. 69. – P. 3005–3018. |
[18] | Chemotherapy Induces Oral Mucositis in Mice Without Additional Noxious Stimuli / M. Bertolini, T. Sobue, A. Thompson, A. Dongari–Bagtzoglou // Translational Oncology. – Vol. 10. – No. 4. – P. 612–620. – doi:10.1016/j.tranon.2017.05.001. |
[19] | Chemotherapy–induced oral mucositis is associated with detrimental bacterial dysbiosis / B.Y. Hong, T. Sobue, L. Choquette, [et al.] // Microbiome. – 2019. – Vol. 7. – No. 1. – P. 66. – doi: 10.1186/s40168–019–0679–5. |
[20] | Chin, D. Novel markers for poor prognosis in head and neck cancer / D. Chin,G. M. Boyle, R. M. Williams // Int. J. Cancer. - 2005. - Vol. 113, № 5. - P. 789-797. |
[21] | Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis. /E.B. Rubenstein, D.E. Peterson, M. Schubert, [et al.] // Cancer. – 2004. – No. 100(9 Suppl). – P. 2026–2046. – doi: 10.1002/cncr.20163. |
[22] | Elad, S. Basic oral care for hematology–oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the joint task force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology. – No. MASCC/ISOO) and the European Society for Blood and Marrow Transplantation. – No. EBMT) / S. Elad, J.E. Raber–Durlacher, M.T. Brennan // Support Care Cancer. – 2015. – Vol. 23. – No. 1. – P. 223–236. |
[23] | Epstein, J.B. Oral and Dental Health in Head and Neck Cancer Patients. Epstein, J. B., Barasch, A. // Cancer treatment and research. – 2018. – Vol. 174. – P. 43 –– https://doi.org/10.1007/978–3–319–65421–8_4. |
[24] | Evaluating the supportive costs of severe radiochemotherapy–induced mucositis and pharyngitis: results from a Northwestern University Cost of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a veterans administration hospital, or a comprehensive cancer center / N.J. Nonzee, N.A. Dandade, U. Patel, [et al.] // Cancer. – 2008. – Vol. 113. – P. 1446–1452. |
[25] | Gabapentin enhances the analgesic effect of morphine in healthy volunteers / K. Eckhardt, S. Ammon, U. Hofmann, [et al.] // Anesth Analg. – 2000. – Vol. 91. – P. 185–191. |
[26] | Goodman, M.K. Integumentary and mucous membrane alterations / M.K. Goodman, L. Ladd // In: Cancer Nursing: Principles and Practice by edition S. Groenwald, M.H. Frogge, M. Goodman, C.H. Yarbro. – Boston: Jones and Bartlett, 1993. – P. 763–788. |
[27] | Grunberg, S. Risk, quality of life impact of mucosal injury among colorectal cancer patients receiving FOLFOX chemotherapy / S. Grunberg, P. Hesketh, P. Randolph-Jackson, [et al.] // Support Care Cancer. – 2007. – Vol. 15. – P. 704. |
[28] | Heimdahl, A. Oral infections in immunocompromised patients / A. Heimdahl, C.E. Nord // J Clin Periodontal. – 1990. – Vol. 17. – P. 501–503. |
[29] | Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors / P. Riley, A.M. Glenny, H.V. Worthington, [et al.] // Cochrane Database Syst Rev. – 2017. – No. 11. – CD011990. – doi:10.1002/14651858.CD011990.pub2. |
[30] | Keskinbora, K. Gabapentin and an opioid combi- nation versus opioid alone for the management of neuropathic cancer pain: a randomized open trial / K. Keskinbora, A.F. Pekel, I.J. Aydinli // Pain Symptom Manage. – 2007. – Vol. 34. – P. 183–189. |
[31] | Lalla, R.V. Chemotherapy or radiation–induced oral mucositis / R.V. Lalla, D.P. Saunders, D.E. Peterson // Dent Clin North Am. – 2014. – Apr. 58. – No. 2. – P. 341– 349. – doi: 10.1016/j.cden.2013.12.005. |
[32] | Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a study pilot / J.J. Napeñas, M.T. Brennan, S. Coleman, [et al.] // Oral Surg Oral Med Oral Pathol Oral Radiol Endod. – 2010. – Apr. 109. – No. 4. – P. 554––560. – doi: 10.1016/j.tripleo.2009.11.015. |
[33] | Mucositis in head and neck cancer: economic and quality–of–life outcomes / A. Peterman., D. Cella, G. Glandon, [et al.] // J Natl Cancer Inst Monogr. – 2001. – No. 29. – P. 45–51. |
[34] | Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: A systematic literature review / A. Trotti, L.A. Bellm, J.B. Epstein J.B., [et al.] // Radiother. Oncol. – 2003. – Vol. 66. – P. 253–262. – doi: 10.1016/s0167-8140(02)00404-8. |
[35] | Nanoencapsulated Doxorubicin Prevents Mucositis Development in Mice / C.M. Pinto, L.S. Horta, A.P. Soares, [et al.] // Pharmaceutics. – 2021. – Jul 4. – Vol. 13. – No. 7. – P. 1021. – doi: 10.3390/pharmaceutics13071021. – PMID: 34371713; PMCID: PMC8329927. |
[36] | Oncological–Therapy Related Oral Mucositis as an Interdisciplinary Problem–Literature Review / A. Kusiak, B.A. Jereczek–Fossa, D. Cichońska, D. Alterio // Int J Environ Res Public Health. – 2020. – Vol. 17. – No. 7. – P. 24–64. – doi:10.3390/ijerph17072464. |
[37] | Palifermin for oral mucositis after intensive therapy for hematologic cancers / R. Spielberger, [et al.] // New Engl J Med. – 2004. – Vol. 351. – P. 2590–2598. |
[38] | Patient–reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life / L.S. Elting, D.M. Keefe, S.T. Sonis, [et al.] – Cancer. – 2008. – Vol. 113. – P. 2704–2713. |